Form 4: Adaptive Biotechnologies President Executes Stock Plan

President and COO Julie Rubinstein exercised options and sold shares of Adaptive Biotechnologies under a Rule 10b5-1 plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies, exercised stock options for 44,166 shares at a strike price of $8.46 over three days.
• The reporting person sold a total of 57,180 shares of common stock between April 22 and April 24, 2026.
• Transactions were executed at weighted average prices ranging from $13.74 to $14.13 per share.
• All sales were conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine equity management by a senior executive.

Positives

• The executive maintains a significant remaining beneficial ownership of 382,132 shares of common stock.
• The transactions were conducted under a pre-arranged 10b5-1 plan, which typically indicates a systematic approach to liquidity rather than reactive trading based on non-public information.

Negatives

• The executive reduced their total beneficial ownership position through the net sale of shares.

Risks

• Future share price volatility could impact the value of the remaining 60,438 unexercised stock options held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive selling under 10b5-1 plans is a standard practice for liquidity and diversification, and does not necessarily reflect a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while avoiding potential conflicts with insider trading regulations.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the systematic nature of the sales mitigates concerns regarding negative sentiment.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Julie Rubinstein, Stock Options, 10b5-1